Extended Data Fig. 9: Evaluation of the effects of MOA compounds on LPS responses in PBMCs.
From: Scalable, compressed phenotypic screening using pooled perturbations
a. Line plots of the number of detected positive/negative LPS response potentiators and interferers per cell type as a function of the p-value cut-off used in permutation tests for the significance of regression coefficients. b. Merimepodib exerts multiple different effects on LPS response modules across cell types. Two-sided Mann-Whitney U test without multiple hypothesis correction was performed to test score differences (Methods). All the box plots indicate 25th percentile at the bottom, median in the middle and 75th percentile at the top. Whiskers are drawn to the farthest datapoints within 1.5* interquartile range from the nearest hinge. Sample sizes in each stimulation condition: DMSO n = 198 (B), n = 1730 (CD4), n = 201 (CD8), n = 396 (monocyte); DMSO + LPS n = 507 (B), n = 3,259 (CD4), n = 61(CD8), n = 1,395 (monocyte); Merimepodib+LPS n = 233 (B), n = 2,865 (CD4), n = 375 (CD8), n = 165 (monocyte). c. Annotation of monocyte cNMF GEP modules from LPS+control condition. d. Annotation of B cell GEPs from LPS+control condition. GEP3 highly correlates with amine biosynthesis/metabolic processes and TNF pathway signatures. e. Annotation of CD8 T cell GEPs from LPS+control condition. GEP3 highly correlates with JAK-STAT pathway signature. f. Annotation of CD4 T cell cNMF GEP modules from LPS+control condition.
